EA201992587A1 - Пептиды и их применение в качестве противовирусных агентов - Google Patents

Пептиды и их применение в качестве противовирусных агентов

Info

Publication number
EA201992587A1
EA201992587A1 EA201992587A EA201992587A EA201992587A1 EA 201992587 A1 EA201992587 A1 EA 201992587A1 EA 201992587 A EA201992587 A EA 201992587A EA 201992587 A EA201992587 A EA 201992587A EA 201992587 A1 EA201992587 A1 EA 201992587A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
application
antiviral agents
viruses
dextrorotatory
Prior art date
Application number
EA201992587A
Other languages
English (en)
Inventor
Мохамед Раджик Мохамед Ибрахим
Original Assignee
Вираматикс Сдн Бхд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вираматикс Сдн Бхд filed Critical Вираматикс Сдн Бхд
Publication of EA201992587A1 publication Critical patent/EA201992587A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем описании раскрыты пептиды, обладающие противовирусными свойствами. Указанные пептиды содержат правовращающие (D) или смесь правовращающих/левовращающих (L)-аминокислот, обладают противовирусными свойствами против множества типов оболочечных вирусов и вирусов, содержащих слой матриксного белка, и являются подходящими для применения в виде фармацевтических композиций для лечения или предотвращения инфекций, вызванных оболочечными вирусами и вирусами, содержащими слой матриксного белка.
EA201992587A 2017-05-26 2017-05-26 Пептиды и их применение в качестве противовирусных агентов EA201992587A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MY2017/050021 WO2018217075A1 (en) 2017-05-26 2017-05-26 Peptides and uses therefor as antiviral agents

Publications (1)

Publication Number Publication Date
EA201992587A1 true EA201992587A1 (ru) 2020-05-08

Family

ID=64396743

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992587A EA201992587A1 (ru) 2017-05-26 2017-05-26 Пептиды и их применение в качестве противовирусных агентов

Country Status (11)

Country Link
US (1) US11376306B2 (ru)
EP (1) EP3638280A4 (ru)
JP (1) JP7233737B2 (ru)
KR (1) KR20200012894A (ru)
CN (1) CN110869040A (ru)
AU (1) AU2017415108A1 (ru)
BR (1) BR112019024796A2 (ru)
CA (1) CA3064544A1 (ru)
EA (1) EA201992587A1 (ru)
MX (1) MX2019013874A (ru)
WO (1) WO2018217075A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
JP7233737B2 (ja) 2017-05-26 2023-03-07 ビラマティクス スンディリアン ブルハド ペプチドおよび抗ウイルス剤としてのその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
WO2001057072A2 (en) 2000-02-07 2001-08-09 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7148404B2 (en) 2004-05-04 2006-12-12 Novozymes A/S Antimicrobial polypeptides
CA2610667A1 (en) 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
US20070073039A1 (en) 2005-09-29 2007-03-29 Chisari Francis V Peptides that inhibit viral infections
GB0718966D0 (en) 2007-09-28 2007-11-07 Liverpool School Of Tropical M Bacterial vaccine
MY160435A (en) 2008-06-12 2017-03-15 Univ Putra Malaysia A novel antiviral peptide against avian influenza virus h9n2
CA2727898A1 (en) 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel antiviral peptides against influenza virus
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201012651D0 (en) 2010-07-28 2010-09-15 Univ Edinburgh Peptides
US9950030B2 (en) 2013-06-27 2018-04-24 Rutgers, The State University Of New Jersey Treatment and diagnosis of ocular disease
WO2016007751A1 (en) 2014-07-09 2016-01-14 Arapeen Medical, LLC Image-guided focused ultrasound ablation
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
JP7233737B2 (ja) 2017-05-26 2023-03-07 ビラマティクス スンディリアン ブルハド ペプチドおよび抗ウイルス剤としてのその使用

Also Published As

Publication number Publication date
CN110869040A (zh) 2020-03-06
US11376306B2 (en) 2022-07-05
CA3064544A1 (en) 2018-11-29
JP2020528072A (ja) 2020-09-17
BR112019024796A2 (pt) 2020-06-16
AU2017415108A1 (en) 2019-12-19
JP7233737B2 (ja) 2023-03-07
EP3638280A4 (en) 2021-01-06
EP3638280A1 (en) 2020-04-22
WO2018217075A1 (en) 2018-11-29
KR20200012894A (ko) 2020-02-05
US20200113967A1 (en) 2020-04-16
MX2019013874A (es) 2020-07-28

Similar Documents

Publication Publication Date Title
CL2023000555A1 (es) Compuestos y métodos para el tratamiento de infecciones virales
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112019006887A2 (pt) ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias
DOP2023000037A (es) Compuestos fosfolípidos y usos de los mismos
BR112022008365A2 (pt) Inibidores de cd73
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
DOP2023000074A (es) Compuestos fosfolípidos y usos de estos
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
ECSP21002804A (es) Apirasas solubilizadas, métodos y usos
BR112018070819A2 (pt) peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA201992587A1 (ru) Пептиды и их применение в качестве противовирусных агентов
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
EA202090143A1 (ru) Фармацевтически приемлемые соли полипептидов и их применение